Matrix Metalloproteinase-10 Promotes Kras-Mediated Bronchio-Alveolar Stem Cell Expansion and Lung Cancer Formation

Roderick P. Regala¹, Verline Justilien¹, Michael P. Walsh¹, Capella Weems¹, Andras Khoo², Nicole R. Murray¹, Alan P. Fields¹*

¹Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida, United States of America, ²Department of Pathology, Mayo Clinic College of Medicine, Jacksonville, Florida, United States of America

Abstract

Matrix metalloproteinase 10 (MMP-10; stromelysin 2) is a member of a large family of structurally related matrix metalloproteinases, many of which have been implicated in tumor progression, invasion and metastasis. We recently identified Mmp10 as a gene that is highly induced in tumor-initiating lung bronchioalveolar stem cells (BASCs) upon activation of oncogenic Kras in a mouse model of lung adenocarcinoma. However, the potential role of Mmp10 in lung tumorigenesis has not been addressed. Here, we demonstrate that Mmp10 is overexpressed in lung tumors induced by either the smoke carcinogen urethane or oncogenic Kras. In addition, we report a significant reduction in lung tumor number and size after urethane exposure or genetic activation of oncogenic Kras in Mmp10 null (Mmp10−/−) mice. This inhibitory effect is reflected in a defect in the ability of Mmp10-deficient BASCs to expand and undergo transformation in response to urethane or oncogenic Kras in vivo and in vitro, demonstrating a role for Mmp10 in the tumor-initiating activity of Kras-transformed lung stem cells. To determine the potential relevance of MMP10 in human cancer we analyzed Mmp10 expression in publicly-available gene expression profiles of human cancers. Our analysis reveals that MMP10 is highly overexpressed in human lung tumors. Gene set enhancement analysis (GSEA) demonstrates that elevated MMP10 expression correlates with both cancer stem cell and tumor metastasis genomic signatures in human lung cancer. Finally, Mmp10 is elevated in many human tumor types suggesting a widespread role for Mmp10 in human malignancy. We conclude that Mmp10 plays an important role in lung tumor initiation via maintenance of a highly tumorigenic, cancer-initiating, stem-like cell population, and that Mmp10 expression is associated with stem-like, highly metastatic genotypes in human lung cancers. These results indicate that Mmp10 may represent a novel therapeutic approach to target lung cancer stem cells.

Introduction

Non-small cell lung cancer (NSCLC) is the most common cause of cancer death in the United States [1]. Despite advances in treatment, clinical outcome of lung cancer patients remains poor. Therefore, there continues to be a need to identify underlying mechanisms of lung tumorigenesis that could lead to more effective means of prevention, diagnosis, prognosis and targeted therapies.

Emerging evidence supports the existence of rare subpopulations of cancer cells with stem-like characteristics [2,3,4]. These cancer-initiating cells or cancer stem cells (CSCs) exhibit self-renewal, tumor-initiating activity, and the ability to support tumor maintenance and metastasis [2,4,5,6]. Thus, CSCs appear to be critical targets for effective, potentially curative cancer treatment. Unfortunately, CSCs exhibit intrinsic resistance to chemotherapy [7,8], underlining the need to identify new therapeutic targets to effectively eradicate CSCs. CSCs share molecular and genomic features with embryonic stem cells, and embryonic stem cell genomic signatures are enriched in highly tumorigenic cancer stem cells. Such CSCs have been described in leukemia [9], and solid tumors, including melanoma [10], breast [11], brain [12,13,14], prostate [15], head and neck [16], pancreatic [17], colon carcinomas [18,19], and lung [20,21].

We recently demonstrated that Mmp10 is required for the transformed growth and invasion of human NSCLC cells in vitro [22]. However, the role of Mmp10 in lung tumorigenesis has not been addressed. Here, we use a combination of mouse carcinogenesis models and analysis of human tumors to demonstrate that Mmp10 plays a novel, unexpected role in Kras-mediated lung cancer initiation, lung cancer stem cell expansion, and metastasis. Our data indicate that Mmp10 is an attractive therapeutic target for CSCs.
Results

Mmp10 loss inhibits Kras-mediated lung tumorigenesis

In order to determine whether Mmp10 is involved in lung tumor formation, mice were treated with the smoke carcinogen urethane to induce lung adenocarcinoma tumors using well-established protocols [23]. Immunohistochemical analysis demonstrated that Mmp10 expression is elevated in urethane-induced tumors, particularly at areas of contact between the tumor and the surrounding stroma (Figure 1A). These results are consistent with previous observations in human NSCLC tumors [22,24,25]. Interestingly, when Mmp10<sup>−/−</sup> mice were exposed to urethane, these mice developed significantly fewer (Figure 1B) and smaller (Figure 1C) tumors, and exhibited a smaller total tumor burden (Figure 1D) than non-transgenic (NTg) littermates. Analysis of tumor grade using the system described by Kelly-Spratt et al. [26] demonstrated that urethane-induced tumors from Ntg and Mmp10<sup>−/−</sup> mice showed a similar distribution of tumors along the hyperplasia-adenoma-carcinoma progression scheme (Figure 1E). These data indicate that Mmp10 plays an important promotive role in urethane-induced lung tumorigenesis primarily at the tumor initiation stage.

Since urethane-induced lung tumorigenesis is thought to be driven, at least in part, through acquisition of kras mutations, we assessed whether Mmp10 plays a similar promotive role in Kras-mediated lung tumorigenesis. For this purpose, we crossed Mmp10<sup>−/−</sup> mice to Kras<sup>L-A</sup> mice, in which spontaneous recombination events lead to activation of a mutant Kras<sup>L-A2</sup> allele in the lung that drives lung tumor formation [27]. Lung tumors in Kras<sup>L-A</sup> mice express elevated Mmp10 that exhibits a similar pattern of expression as in urethane-induced lung tumours (Figure 2A). Similar to our observation in urethane-treated mice, bitransgenic Kras<sup>L-A2</sup>/Mmp10<sup>−/−</sup> mice developed fewer (Figure 2B) and smaller (Figure 2C) tumors, and exhibit lower overall tumor burden (Figure 2D) than Kras<sup>L-A</sup> mice. Analysis of tumor grade using the scoring system devised by Jackson et al. [28] demonstrated that ~16% of tumors in Kras<sup>L-A</sup> mice were high grade adenocarcinomas (grade 3), whereas less than 1% of the tumors in Kras<sup>L-A2</sup>/Mmp10<sup>−/−</sup> mice were grade 3 (Figure 2E). These data suggest that Mmp10 in this model is important in both tumor initiation and progression. Taken, together our data indicate that Mmp10 plays an important role in multiple models of lung tumor formation.

Mmp10 is required for Kras-mediated bronchio-alveolar stem cell expansion in vivo

The fact that Mmp10-deficient mice develop fewer Kras-mediated lung tumors suggests that Mmp10 is involved in the initiating steps of Kras-mediated lung tumorigenesis in vivo. Initiation of Kras-mediated lung tumors is thought to involve clonal expansion of Kras-transformed bronchio-alveolar stem cells (BASCs), putative regional stem cells that reside at the terminal bronchioles adjacent to the alveolar space [29]. Therefore, we assessed whether Mmp10-deficiency affects the expansion of BASCs in response to urethane and oncogenic Kras in vivo. We identified and quantitated BASCs in paraffin sections of mouse lungs by dual immunofluorescence staining for surfactant protein C (SPC) and the Clara cell-specific protein (CCSP) as described previously [29,30]. BASCs are observed at the bronchioalveolar duct junctions at terminal bronchioles as double SPC/CCSP positive cells (Figure 3A). Either urethane treatment or the presence of oncogenic Kras caused an expansion of BASCs at the terminal bronchioles (Figure 3A). Quantitative analysis of lung tissue sections from Ntg and Mmp10<sup>−/−</sup> mice in the absence or presence of urethane showed that urethane-treated Ntg mice exhibit a significant increase in the number of BASCs per terminal bronchiol (BASCs/TB) when compared with control Ntg mice (Figure 3B). Urethane-treated Mmp10<sup>−/−</sup> mice showed a highly significantly diminution in BASC expansion, such that the distribution and number of BASCs was not significantly different from untreated Ntg mice (Figure 3B). A similar inhibition of oncogenic BASC expansion was observed in Kras<sup>L-A2</sup>/Mmp10<sup>−/−</sup> mice in vivo when compared to Kras<sup>L-A2</sup> mice (Figure 3C). Therefore, in two independent models of Kras-mediated lung tumorigenesis, we observed that Mmp10 deficiency leads to significant decreases in lung tumor number, size and burden; and in each model, the inhibitory effect of Mmp10 deficiency on tumorigenesis was reflected in a defect in the oncogenic expansion of BASCs in vivo. Interestingly, Mmp10 deficiency does not appear to have an effect on BASC homeostasis per se since BASC number and distribution in Mmp10<sup>−/−</sup> mice is not significantly different from that of Ntg mice. Rather, Mmp10 appears to be important for oncogenic expansion of BASCs in response to urethane or Kras activation.

Mmp10 is required for Kras-mediated BASC transformation in vitro

Given the importance of BASCs in tumor initiation, and the inhibitory effect of Mmp10 loss on Kras-mediated BASC expansion in vivo, we assessed the role of Mmp10 in Kras-mediated BASC expansion and transformation in vitro. For this purpose, we utilized LSL-Kras mice, a model in which a conditional lox-stop-lox (LSL) Kras allele can be activated by Cre-mediated recombination [31]. BASCs were isolated from Ntg, LSL-Kras, and LSL-Kras/Mmp10<sup>−/−</sup> mice and characterized for enrichment of BASCs using dual immunofluorescence and flow cytometry. Our BASC preparations consisted of >86% SPC/CCSP double positive cells when analyzed by flow cytometry confirming isolation of a highly enriched BASC population (Figure 4A). Treatment of BASCs from LSL-Kras mice with adenovirus expressing Cre-recombinase (AdCre) to activate the oncogenic kras allele led to a significant increase in Mmp10 mRNA abundance, whereas AdCre-treated BASCs from LSL-Kras/Mmp10<sup>−/−</sup> mice expressed no detectable Mmp10 mRNA as expected (Figure 4B). These results confirm our previous finding that Mmp10 expression is induced in BASCs after expression of oncogenic Kras [30]. AdCre treated BASCs from Ntg or Mmp10<sup>−/−</sup> mice form small, highly organized spherical colonies when plated in three dimensional Matrigel culture of similar size and number (Figure 4C). In contrast, AdCre treated BASCs from LSL-Kras mice grow as larger amorphic, disorganized colonies characteristic of Kras-mediated transformation (Figure 4C, middle panel; [30]). AdCre treated BASCs from LSL-Kras/Mmp10<sup>−/−</sup> mice form colonies similar in size, number and morphology to those from Ntg and Mmp10<sup>−/−</sup> mice (Figure 4C). Quantitative analysis confirmed that BASC colonies from LSL-Kras mice are of larger diameter than colonies from Ntg, Mmp10<sup>−/−</sup> or LSL-Kras/Mmp10<sup>−/−</sup> BASCs (Figure 4D). Thus, Mmp10 is required for oncogenic Kras-induced morphological transformation and expansion of BASCs in vitro but has no appreciable effect on the maintenance of non-transformed BASCs in culture.

Mmp10 expression is associated with stem cell signatures and metastasis in human lung cancer

We previously demonstrated that Mmp10 is overexpressed in human NSCLC and is important for transformed growth and invasion of human NSCLC cells in vitro [22]. Given the
Figure 1. Mmp10 plays a promotive role in urethane-induced lung tumorigenesis. Mmp10<sup>−/−</sup> mice and Ntg littermates were injected with urethane and analyzed as described in Materials and Methods. A) H & E and immunohistochemical staining for Mmp10 in urethane-induced lung tumors. Higher magnification image of Mmp10 immunostaining is shown in the inset. Quantitative analysis of tumor number B), tumor size C) and tumor burden D) in urethane-treated Ntg (n = 7) and Mmp10<sup>−/−</sup> (n = 12) mice. Mean ± SEM; p < 0.012 tumor number; p < 0.019 tumor burden; p = 0.034 tumor size). E) Urethane-induced tumors from Ntg and Mmp10<sup>−/−</sup> mice were graded as hyperplasia, adenoma or adenocarcinoma using published criteria [26]. Results are presented as the percentage of total tumors of each grade. Statistical analysis using Mann-Whitney U test revealed no statistically significant difference in tumor grade between urethane-induced tumors in Ntg and Mmp10<sup>−/−</sup> mice (p = 0.39).

doi:10.1371/journal.pone.0026439.g001
unexpected role of Mmp10 in expansion of Kras\textsuperscript{LA2}-transformed mouse lung BASC and tumor initiating activity, we computationally explored the relationship between Mmp10 expression, cancer stem cell expression profiles and metastasis in human lung cancers. For this purpose, we divided a publicly-available dataset consisting of genome-wide expression analysis of human lung adenocarcinomas (GSE11969) into two equal sized groups of 30 samples comprised of the tumors with the highest (High) and lowest (Low)
Figure 3. MMP10 is required for urethane- and Kras-induced BASC expansion in vivo. A) Immunofluorescent analysis of CCSP (green) and SPC (red) dual positive BASCs (white arrows) in terminal bronchioles (TB) of control Ntg, and urethane-treated Ntg and Mmp10−/− mice (upper panels). B) Quantitative analysis of BASCs in control Ntg, and urethane treated Ntg and Mmp10−/− mice. C) Quantitative analysis of BASCs in lung TBs of Ntg, KrasLA2 and KrasLA2/Mmp10−/− mice. Columns, percentage of TBs; bars = SEM, n = 50 TBs/genotype; p < 0.0005 urethane treated Ntg vs. Mmp10−/−; p < 0.0001 untreated Ntg vs. urethane treated Ntg; No significant difference between untreated non-Ntg vs. urethane treated Mmp10−/− mice. doi:10.1371/journal.pone.0026439.g003

Mmp10 RNA expression, respectively. Statistical analysis confirmed these two groups of samples express significantly different levels of Mmp10 mRNA (Figure 3A). We then performed gene set enrichment analysis (GSEA) against gene sets available as part of the Molecular Signatures Database (MSig) Version 3.0 as described in Materials and Methods to measure any association between Mmp10 and cancer stem cell gene expression profiles. Gene sets were identified by searching the MSig database for gene signatures containing the terms “cancer” and “stem” within their descriptions. GSEA revealed that 37 of the 50 (74%) cancer stem cell signatures were enriched in the high Mmp10 samples, and that 14 signatures were significantly enriched with a p-value < 0.05 and FDR < 25% (Table 1). Interestingly, only 1/50 stem cell signature was enriched in the low Mmp10 samples. This signature described genes that are downregulated in glioma stem cells, [32], further supporting the association of high Mmp10 with the cancer stem cell genotype. A separate GSEA using an independent lung adenocarcinoma gene expression data set (GSE13213) validated our initial analysis. 44/50 stem cell signatures were enriched in high Mmp10 tumor samples and none were enriched in the low Mmp10 tumor samples from this second data set. 10 stem cell gene sets were significantly enriched with a p-value < 0.05 (Table 2), of which seven were also significantly enriched in the first lung adenocarcinoma gene set. These data provide compelling evidence that high Mmp10 expression in human NSCLC tumors is associated with a cancer stem-like gene expression profile.

We also performed an unbiased analysis using every gene set in the MSig database. In this analysis, the top stem cell signatures remained significantly enriched (data not shown). Table 3 shows the most highly significant gene signatures associated with high Mmp10. Significantly, 3 of the top 5 gene sets identified contain Mmp10 as part of the signature. The top scoring gene set describes a signature comprised of genes over-expressed in early stage head and neck tumors suggesting an involvement in early tumorogenesis [33]. Among the gene sets that significantly correlate with high Mmp10 expression, many related to tumor progression, poor clinical outcome and metastatic potential. To specifically explore the association between Mmp10 and lung tumor metastasis, we analyzed a third gene expression dataset from early stage human lung adenocarcinoma samples that had produced a metastasis in bone tissue compared to samples that had not [34]. Analysis revealed that Mmp10 expression was significantly elevated in the primary tumors that produced metastases when compared to normal lung tissue but not in those that did not, indicating an association between Mmp10 expression and metastatic potential (Figure 5B). Interestingly, GSEA of the metastatic lung cancer gene set demonstrated a highly significant correlation with 10 stem cell signatures (p-value < 0.05 and FDR < 25%), four of which were also among the most significant gene sets identified using GSEA of the high Mmp10 lung adenocarcinomas (Table 4). These latter results reveal an association between metastatic potential and stem-like characteristics in primary human lung adenocarcinomas.

Given the importance of elevated Mmp10 expression in human lung cancer biology, we next assessed whether Mmp10 expression was also elevated in other forms of human cancer. Gene expression profiling revealed that Mmp10 is commonly overexpressed in many forms of human cancer, including lung, head and neck, esophageal, bladder, skin, colorectal, breast, cervical, nasopharyngeal, tongue and pancreatic cancers (Figure 5C and Table 5), suggesting a widespread role for Mmp10 in human malignancy.

Discussion

Increasing evidence suggests that many cancers, including lung cancer, possess a small subpopulation of cells that exhibit hallmark traits of stem cells. These “cancer stem cells” are thought to be...
responsible for the initiation, maintenance, progression and metastatic spread of tumors. Most current treatment modalities for lung cancer ultimately fail, perhaps due to intrinsic resistance of CSCs to therapy, resulting in disease recurrence and decreased patient survival. Therefore, molecular characterization of the mechanisms that govern the survival and growth of CSCs may hold a vital key to developing more effective therapeutic strategies that will improve the clinical outcome of patients with lung cancer.

The matrix metalloproteinases (MMPs) have long been implicated in tumor progression and metastasis. We recently demonstrated that Mmp10 is overexpressed in NSCLC and is a critical target of oncogenic \textit{Kras} required for transformed growth and invasion of human NSCLC cells \textit{in vitro} [22]. Our current study provides compelling evidence that Mmp10 exerts its protumorigenic effects, at least in part, by maintaining a population of CSCs that drive tumor initiation and metastasis. Not only is Mmp10 elevated in tumors developed in two different mouse models of \textit{Kras}-induced lung adenocarcinoma, genetic knock out of \textit{Mmp10} leads to formation of significantly fewer tumors, suggesting an effect of Mmp10 on tumor initiation. Consistent with this conclusion, Mmp10 abundance is highly elevated in BASCs transformed with oncogenic \textit{Kras} [30], and genetic loss of \textit{Mmp10} leads to a failure of BASCs expressing oncogenic \textit{Kras} to expand \textit{in vivo}, and undergo morphological transformation \textit{in vitro}. Though it is still unclear whether BASCs represent regional lung stem cells, strong circumstantial evidence indicates that they are involved in tumor initiation in the mouse lung. BASCs undergo expansion and transformation in response to \textit{Kras} activation [29], and genetic and/or pharmacological disruption of multiple key oncogenic pathway genes involved in \textit{Kras}-mediated tumorigenesis, including \textit{Ptk2} [30], \textit{Pik3ca} [35], and \textit{Bmi1} [36], lead to inhibition of BASC expansion and \textit{Kras}-mediated tumor formation \textit{in vivo}. On the other hand, recent studies have demonstrated that both Scal" (including BASCs) and Scal" cells exhibit tumor-initiating activity in \textit{Kras} mice, demonstrating that BASCs are not the sole source of tumor-initiating cells in this model [37]. These findings indicate

---

\textbf{Figure 4. Mmp10 is required for \textit{Kras}-induced expansion and transformation of BASCs \textit{in vitro}.} BASCs isolated from Ntg, Mmp10\textsuperscript{+/−}, LSL-Kras, and LSL-Kras/Mmp10\textsuperscript{+/−} mice were treated with AdCre and plated in three-dimensional Matrigel culture as described in \textit{Experimental Procedures}. A) Flow cytometry of isolated BASCs for SPC and CCSP B) QPCR for Mmp10 in BASCs from Ntg, LSL-Kras, and LSL-Kras/Mmp10\textsuperscript{+/−} mice. Fold of Ntg +/- SEM. n = 3, *p<0.000008. C) Morphology of BASC colonies from Ntg, Mmp10\textsuperscript{+/−}, LSL-Kras, and LSL-Kras/Mmp10\textsuperscript{+/−} mice. D) Analysis of BASC colony size. %Ntg +/- SEM. n = 85 Ntg, 56 Mmp10\textsuperscript{+/−}, 80 (LSL-Kras) and 80 (LSL-Kras/Mmp10\textsuperscript{+/−}). *p<0.00001 Ntg vs. LSL-Kras; **p<0.00001 LSL-Kras vs. LSL-Kras/Mmp10\textsuperscript{+/−}. doi:10.1371/journal.pone.0026439.g004

---

\textit{Mmp10} leads to formation of significantly fewer tumors, suggesting an effect of Mmp10 on tumor initiation. Consistent with this conclusion, Mmp10 abundance is highly elevated in BASCs transformed with oncogenic \textit{Kras} [30], and genetic loss of \textit{Mmp10} leads to failure of BASCs expressing oncogenic \textit{Kras} to expand \textit{in vivo}, and undergo morphological transformation \textit{in vitro}. Though it is still unclear whether BASCs represent regional lung stem cells, strong circumstantial evidence indicates that they are involved in tumor initiation in the mouse lung. BASCs undergo expansion and transformation in response to \textit{Kras} activation [29], and genetic and/or pharmacological disruption of multiple key oncogenic pathway genes involved in \textit{Kras}-mediated tumorigenesis, including \textit{Ptk2} [30], \textit{Pik3ca} [35], and \textit{Bmi1} [36], lead to inhibition of BASC expansion and \textit{Kras}-mediated tumor formation \textit{in vivo}. On the other hand, recent studies have demonstrated that both Scal" (including BASCs) and Scal" cells exhibit tumor-initiating activity in \textit{Kras} mice, demonstrating that BASCs are not the sole source of tumor-initiating cells in this model [37]. These findings indicate
that tumor genotype is an important determinant of tumor-initiating cells. In humans, lung adenocarcinomas, which frequently harbor \textit{Kras} mutations, often develop at the bronchio-alveolar duct junction and display either airway or alveolar differentiation, or both [38], suggesting that some of these tumors may have originated from BASC-like cells.

Our data provide evidence that the role of \textit{Mmp10} in lung CSCs is cell autonomous. Both the \textit{Kras} \textit{L/L2} and urethane tumor models show Mmp10 staining in tumor cells, with little to no staining in tumor associated-stroma or morphological normal lung epithelium. More importantly, the tumor inhibitory effects of the genetic loss of Mmp10 are reflected in a defect in oncogenic expansion of BASCs \textit{in vivo} and \textit{in vitro}. Thus, while many MMPs produced by the tumor microenvironment play prominent roles in the invasive and metastatic properties of lung tumor cells, our data demonstrate that Mmp10 specifically functions to support the autonomous growth of CSCs. However, our data do not exclude a contributory role for Mmp10 produced by and/or exerting its effects upon the tumor microenvironment. However, our studies do provide new insight into a largely unappreciated role for Mmp10 in the regulation of CSC behavior. Interestingly, Mmps have been implicated in regulation of tumor cell growth through cleavage and activation of cell surface proteins involved in cell growth regulation such as Notch [39,40], and through proteolytic

**Figure 5.** Mmp10 expression correlates with cancer stem cell genotypes and metastasis in human lung tumors. A) Gene expression data from primary human lung adenocarcinomas were divided into two groups of 30 samples consisting of lowest (Low) and highest (High) Mmp10 expressing lung tumors. \( n = 30; \ast p = 2.8 \times 10^{-33} \). B) Mmp10 in normal lung versus lung tumors with (Met) and without (No Met) bone metastases. \( n = 3, \) normals, \( n = 9, \) No Mets, \( n = 7, \) Met; NS = not significant, \( \ast p = 0.008; \ast \ast p = 0.04. \) C) Mmp10 mRNA expression in human tumors. Data are expressed as fold-change from matched normal. doi:10.1371/journal.pone.0026439.g005
liberation of active growth factors such as TGFβ, IGF and TNFα from latent extracellular stores [41]. Future studies will focus on determining the specific molecular mechanisms that contribute to Mmp10-mediated CSC proliferation.

Cancer stem cells (CSCs) are defined by their ability to clonally expand, initiate tumors, maintain tumor progression and participate in tumor metastasis. The phenotype of these cells is associated with a genotype related to that of embryonic stem cells. Our finding that Mmp10 expression is associated with CSC genotypes in human lung tumors provides compelling circumstantial evidence that Mmp10 plays a critical role in maintenance of CSCs within human lung tumors. In this regard, it is interesting to note that Mmp10 expression has been observed to be elevated in tumor-initiating stem-like cells isolated from human small cell lung cancer cell lines [42], suggesting that Mmp10 may also function in the maintenance of these CSCs.

The leading cause of cancer-related deaths in lung cancer patients is metastatic dissemination. CSCs are thought to be the cells within a tumor that have the capability of metastasizing to distant sites. Our finding that Mmp10 is highly expressed in lung cancer-initiating BASCs, and is associated with the CSC genotype in human lung tumors suggests that Mmp10 may promote both CSC maintenance and metastatic potential through its role in CSC proliferation and metastatic behavior. Our finding that Mmp10 is elevated in human CSCs and that Mmp10 is highly expressed at the interface between mouse lung tumors and the surrounding tissue, suggesting a role for Mmp10 in tumor invasion, and are consistent with our previous funding that Mmp10 is required for invasion of human NSCLC cells in vitro [22]. These areas of increased Mmp10 staining may represent resident CSCs. The fact that Mmp10 is more highly expressed in tumors with high metastatic potential, and in the metastatic lesions of these tumors is consistent with the proposed role of CSC in metastatic spread. However, we cannot formally rule out an additional role for Mmp10 in bulk tumor cells that contributes to the metastatic potential of tumors. Our expression profiling data of human tumors demonstrates a close functional link between CSC, Mmp10 expression and metastatic potential, suggesting that Mmp10 plays a similar role in human lung adenocarcinoma CSC invasion and metastasis. Our results also demonstrate that

| Table 1. Cancer Stem Cell Signatures correlate with high Mmp10 expression in lung cancer. |
|---------------------------------|-----------------|---------|---------|----------|---------|----------------|---|
| Signature Name/Description     | Size (genes)    | ES      | NES     | P-value  | FDR     | Reference       |   |
|--------------------------------|-----------------|---------|---------|----------|---------|----------------|---|
| Embryonic Stem Cell (ESC)-proliferation | 111             | 0.44    | 2.11    | <0.0001  | 0.003    | [54]            |   |
| ESC-core signature             | 268             | 0.34    | 1.86    | <0.0001  | 0.015    | [55]            |   |
| ESC-gene set 1                 | 285             | 0.3     | 1.65    | <0.0001  | 0.059    | [54]            |   |
| ESC-NOS targets                | 136             | 0.3     | 1.48    | 0.014    | 0.156    | [54]            |   |
| ESC-PRC2 targets               | 489             | 0.24    | 1.4     | 0.002    | 0.23     | [54]            |   |
| ESC-SUZ12 targets              | 765             | 0.23    | 1.38    | <0.0001  | 0.23     | [54]            |   |
| ESC-Oct4 targets               | 228             | 0.25    | 1.35    | 0.023    | 0.21     | [54]            |   |
| ESC-EED targets                | 778             | 0.21    | 1.29    | 0.002    | 0.21     | [54]            |   |
| ESC-cycling genes              | 460             | 0.22    | 1.25    | 0.027    | 0.24     | [54]            |   |
| Breast cancer progenitor cells | 266             | 0.24    | 1.32    | 0.021    | 0.22     | [56]            |   |
| ESC-H3K27 ME3                  | 830             | 0.21    | 1.29    | 0.002    | 0.23     | [54]            |   |
| ESC-Myc-Max targets            | 653             | 0.21    | 1.24    | 0.015    | 0.23     | [54]            |   |
| ESC-Sox2 targets               | 509             | 0.21    | 1.22    | 0.018    | 0.22     | [54]            |   |
| ESC-Nanog targets              | 694             | 0.2     | 1.17    | 0.036    | 0.25     | [54]            |   |

| Table 2. Validation of the association between high Mmp10 in lung tumors and cancer stem cell signatures. |
|---------------------------------|-----------------|---------|---------|----------|---------|----------------|---|
| Gene Set                        | Size (genes)    | ES      | NES     | p-value  | Reference       |   |
|---------------------------------|-----------------|---------|---------|----------|----------------|---|
| ESC-Proliferation               | 143             | 0.5     | 2.14    | <0.0001  | [54]            |   |
| Breast cancer progenitor cells UP| 370             | 0.38    | 1.8     | <0.0001  | [56]            |   |
| Breast cancer-tamoxiphen resistance | 49              | 0.49    | 1.72    | 0.025    | [57]            |   |
| UV response cluster G4          | 13              | 0.65    | 1.72    | 0.044    | [58]            |   |
| ESC-ES geneset 1                | 370             | 0.33    | 1.56    | 0.004    | [54]            |   |
| Leukemic stem cells             | 234             | 0.34    | 1.53    | 0.007    | [59]            |   |
| ESC-EED Targets                 | 1002            | 0.26    | 1.36    | 0.009    | [54]            |   |
| ESC-cycling genes               | 630             | 0.26    | 1.32    | 0.023    | [54]            |   |
| ESC-H3K27 ME3                   | 1058            | 0.24    | 1.25    | 0.018    | [54]            |   |
| ESC-SUZ12 Targets               | 979             | 0.24    | 1.25    | 0.037    | [54]            |   |

Gene sets marked in bold text were also significantly enriched in the high Mmp10 lung tumor gene set analysis outlined in Figure 5 and Table 1.

doi:10.1371/journal.pone.0026439.t002
MMP10 is highly expressed in many human tumor types, and is associated with poor outcome, metastatic potential and cancer stem cell signatures. These findings suggest a widespread role for MMP10 in human malignancy and identify it as a novel therapeutic target in cancer stem cells.

**Materials and Methods**

**Mouse Urethane- and Kras<sup>LA2</sup>-mediated Lung Tumorigenesis Studies**

Nullizygous *Mmp10* (-/-) mice were obtained from the National Cancer Institute Mutant Mouse Regional Resource Center (MMRRC). The mice were generated on a mixed 129/C57BL/6J background and harbor a targeted disruption of exons 1–3 of the mouse *Mmp10* gene. The mice were bred onto a pure C57BL/6J background through 10 generations. Genotyping was conducted by PCR using primers recommended by MMRRC.

*Mmp10* / / mice and non-transgenic littermates were injected intraperitoneally with urethane at 1 mg/kg body weight weekly for six weeks to induce lung tumors. Control mice were injected with saline. Mice were analyzed twelve weeks after the first injection for the presence of pulmonary lesions. *Kras<sup>LA2</sup>* mice, generated as previously described [27], were mated with *Mmp10* / / mice to generate bitransgenic *Kras<sup>LA2</sup>/Mmp10* / / mice. *Kras<sup>LA2</sup>* and *Kras<sup>LA2</sup>/Mmp10* / / mice were harvested at the time points indicated to assess tumor number, tumor size, tumor burden and pathological classification by a board-certified pathologist (A.K.). *Mmp10* / / and non-transgenic mice served as negative controls. All animal experiments were approved by the Institutional Animal Care and Use Committee of Mayo Clinic and were conducted under approved IACUC protocol # A30308. Mouse tissues were prepared for histology and immunohistochemistry as previously described [30, 43]. Sections were stained for Mmp10 (NBP1-03118; Novus Biologicals, Littleton, CO) and antigen visualized using the Envision Plus

### Table 3. The 10 most highly correlated signatures associated with high Mmp10 in lung cancer.

| Gene Set Name                                      | Size (genes) | ES  | NES  | p-value     | FDR   | Reference |
|----------------------------------------------------|--------------|-----|------|-------------|-------|-----------|
| Upregulated in early stage Head and Neck tumors vs. normal | 43           | 0.75| 2.65 | <0.0001     | <0.0001| [33]      |
| Up regulated in colon adenomas vs. normal mucosa    | 128          | 0.6 | 2.51 | <0.0001     | 0.001 | [60]      |
| Upregulated in breast cancer                       | 19           | 0.85| 2.41 | <0.0001     | 0.009 | [61]      |
| Up regulated in basal mammary epithelial cells vs. luminal | 53           | 0.67| 2.4  | <0.0001     | 0.007 | [62]      |
| Upregulated in cervical cancers and associated with proliferation and poor outcome | 140          | 0.56| 2.38 | <0.0001     | 0.011 | [63]      |
| Upregulated in NSCLC and predict poor survival      | 445          | 0.48| 2.37 | <0.0001     | 0.012 | [64]      |
| Up regulated in in advanced vs early gastric cancers | 162          | 0.55| 2.35 | <0.0001     | 0.016 | [65]      |
| Up regulated in nasopharyngeal carcinoma vs. normal | 272          | 0.5 | 2.31 | <0.0001     | 0.026 | [66]      |
| Up regulated in invasive ductal breast carcinoma vs. carcinoma in situ | 343          | 0.49| 2.31 | <0.0001     | 0.024 | [67]      |
| Up regulated in breast ductal carcinoma vs. normal | 66           | 0.6 | 2.3  | <0.0001     | 0.024 | [68]      |

Gene sets marked in bold text contain Mmp10 as part of the gene signature.

doi:10.1371/journal.pone.0026439.t003

### Table 4. Association of metastatic lung cancer genes with cancer stem cell signatures.

| Gene Set Name       | Size (genes) | ES  | NES  | p-value     | FDR   | Reference |
|---------------------|--------------|-----|------|-------------|-------|-----------|
| UV Response Cluster G4 | 14           | 0.67| 1.86 | 0.005       | 0.015 | [58]      |
| Response to UV NHEK UP | 146          | 0.41| 1.82 | <0.0001     | 0.012 | [58]      |
| UV Response Cluster G3 | 11           | 0.66| 1.68 | 0.011       | 0.043 | [58]      |
| Silenced by Methylation in Colon Cancer | 42           | 0.44| 1.58 | 0.015       | 0.08  | [69]      |
| TP63 Gamma Targets | 9            | 0.65| 1.57 | 0.035       | 0.069 | [70]      |
| ESC-EED Targets      | 921          | 0.29| 1.51 | <0.0001     | 0.107 | [54]      |
| Cancer Progenitors   | 61           | 0.37| 1.45 | 0.025       | 0.129 | [54]      |
| ESC-PRC2 Targets     | 566          | 0.28| 1.44 | <0.0001     | 0.124 | [54]      |
| ESC with H3K27ME3     | 991          | 0.27| 1.44 | <0.0001     | 0.111 | [54]      |
| ESC SUZ12 Targets    | 906          | 0.25| 1.33 | <0.0001     | 0.222 | [54]      |

Gene sets marked in bold text are cancer stem cell signatures also identified as highly correlated with lung tumors expressing high Mmp10.

doi:10.1371/journal.pone.0026439.t004
Dual Labeled Polymer Kit (DAKO). Images were analyzed using the ScanScope scanner and ImageScope software (Aperio Technologies, Vista, CA).

**BASC detection, isolation and culture ex vivo**

BASCs were quantified in formalin fixed, paraffin embedded mouse lung tissues as described previously [30,35]. 

**LSL-Kras** mice [44] were crossed with **Mmp10**/2 mice to generate bitransgenic LSL-Kras/Mmp10/2 mice. Lung epithelial cells were isolated from Ntg, Mmp10/2, LSL-Kras, and LSL-Kras/Mmp10/2 mice and BASC isolation, Cre-recombinase treatment and ex vivo culture were carried out as described previously [30]. Brightfield images of BASC colonies were captured on an Olympus IX71 inverted microscope. BASC colony size was assessed using Image-Pro Plus 6.3 (Media Cybernetics, Bethesda, MD). BASCs were recovered from Matrigel culture for QPCR analysis using BD cell recovery solution (BD Biosciences).

**RNA isolation and quantitative PCR**

Total RNA was extracted from BASC cells using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). QPCR reagents for mouse Mmp10 mRNA were purchased from Applied Biosystems (Foster City, CA). QPCR was carried out using an Applied Biosystems 7900 thermal cycler, and data was analyzed using the SDS 2.3 software package. Data were normalized to 18S RNA.

**Flow cytometry**

BASCs were incubated for 1 hour at 4°C with Alexa Fluor 488-conjugated CD133 (Millipore, Billerica, MA) and Alexa Fluor 647 conjugated Notch4 (Biogenex, San Diego, CA) antibodies or respective isotype controls. Cells were incubated for 1 hour at 4°C with CCSP (Upstate, Temecula, CA) and SPC (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies followed by a 30 minute incubation with Alexa Fluor 488- and Alexa Fluor 647 conjugated secondary antibodies (Invitrogen, Carlsbad, California). Flow cytometry was performed on an Accuri C6 flow cytometer and analyzed using CFlow Plus software (Accuri Cytometers, Inc., Ann Arbor, MI).

**Statistical analysis**

Differences in the number and distribution of BASCs in the terminal bronchioles were assessed using the Cochrane-Armitage test using StatsDirect 2.6.1. Differences in tumor grade were assessed using the Mann-Whitney U test in Stats-Direct 2.6.1. The Student’s \( t \) test and one-way ANOVA statistical analyses were done using SigmaStat 3.5. A \( P \) value of less than 0.05 was considered statistically significant.

**Assessment of Mmp10 in primary human cancer datasets**

The correlation between Mmp10 and various types of human cancer was determined using the NextBio data mining framework (www.nextbio.com) [45]. The degree of correlation calculated by NextBio was based on Mmp10 values for individual microarray studies of specific cancer types. Selected gene expression experiments were chosen for a more in depth analysis The Gene Expression Omnibus (GEO) accession numbers for these studies were: GSE3292, GSE3292, GSE6631, GSE6059, GSE3564, GSE14999, GSE3167, GSE13507, GSE7553, GSE7553, GSE4183, GSE8671, GSE1987, GSE10799, GSE76791, GSE18105, GSE11117, GSE15597, GSE9044, GSE23400.
Cancer Data Sets
Gene Set Enrichment Analysis (GSEA) of Human Lung Cancer Data Sets

Three lung cancer gene expression datasets were analyzed to assess the relationships between Mmp10 levels, the cancer stem cell phenotype and metastasis in human cancer. The first two data sets (GSE11969 and GSE13213) are comprised of gene expression measurements from NSCLC tumors. [46,47]. The third dataset (GSE10799) contained expression values from human lung adenocarcinoma samples that had produced metastasis in bone tissue compared to samples that had not [34]. All three of the microarray datasets were downloaded from GEO into the “R statistical computing language” using the “GEOquery” package of the “Bioconductor” software suite [48,49,50]. Quantile normalization of the dataset was performed using the “preprocess core” module [49,51]. GSE11969 and GSE13213 were sorted according to their Mmp10 expression values. Lung tumor samples in GSE11969 were segregated into two sets. The first set contained the 30 samples with the highest Mmp10 expression values and the second set the 30 samples with the lowest Mmp10 expression values. GSE13213 was treated in the same manner except samples were separated into groups of 35 instead of 30. The size of the groups was determined to maximize the statistical significance of differential Mmp10 expression in each group as determined by a Welch’s t-test.

References

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111.
3. Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumour stem cells. Oncogene 23: 7274–7282.
4. Jordan CT, Guzman ML, Noble M (2006) Cancer Stem Cells. N Engl J Med 355: 1253–1261.
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, et al. (2006) Cancer Cell 15: 941–950.
6. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, et al. (2006) Cancer Cell 15: 941–950.
7. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, et al. (2007) Identification of uPAR-positive Chemoresistant Cells in Small Cell Lung Cancer. PLoS ONE 2: e243.
8. Ho MM, Ng AV, Lam S, Hung JT (2007) Side Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells. Cancer Research 67: 4827–4833.
9. Bonnet DaD, E J (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–737.
10. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas. Cancer Research 65: 9326–9337.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences USA 100: 3983–3988.
12. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Research 63: 5821–5827.
13. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396–401.
14. Galli R, Binda E, Orfaneli U, Cipelletti B, Gritti A, et al. (2004) Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma. Cancer Research 64: 7011–7021.
15. Patrawala L, Calhoun T, Schneider-Brousaud R, Li H, Bhatia B, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696–1708.
16. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences 104: 973–978.
17. Li G, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of Pancreatic Cancer Stem Cells. Cancer Research 67: 1030–1037.
18. Bevacizumab plus Paclitaxel for Metastatic Non-Small-Cell Lung Cancer: A Randomized Phase II Study. J Clin Oncol 24: 3889–3896.
19. O’Brien CA, Pollet A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 454: 106–110.
20. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, et al. (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery 36: 446–453.
21. Eramo A, Lotti F, Sette G, Pilozi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504–514.
22. Frederick LA, Matthews JA, Jamieson J, Justilien V, Thompson EA, et al. (2008) Matrix metalloproteinase-10 is a critical effector of protein kinase Csi-Partially-mediated lung cancer. Oncogene 27: 4841–4853.
23. Malkinson AM, Nesbitt MN, Skamene E (1983) Susceptibility to urethan-induced pulmonary adenomas between A/J and C57BL/6j mice: use of AXB and BXA recombinant inbred lines indicating a three-locus genetic model. J Natl Cancer Inst 75: 971–974.
24. Choo NH, Hong KP, Hong SH, Kang S, Chyung KY, et al. (2004) MMP expression profiling in recurrent stage IB lung cancer. Oncogene 23: 845–851.
25. Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, et al. (2004) MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 6: 777–785.
26. Kelly-Spratt KS, Philipp-Stehl J, Gurley KE, Hoon-Kim K, Kneblbaugh S, et al. (2009) Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene 28: 3652–3662.
27. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer. Neoplasia 6: 777–785.
28. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, et al. (2005) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery 36: 446–453.
29. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, et al. (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823–835.

Author Contributions
Conceived and designed the experiments: RPR VJ MPW APF. Performed the experiments: RPR VJ MPW CW. Analyzed the data: RPR VJ MPW CW AK NRM APF. Wrote the paper: RPR VJ MPW APF.

Acknowledgments
The authors thank Dr. Lee Jamieson, Justin Weems and Dr. Eda Erdogan for assistance with animal procedures and Brandy Edenfield for immunohistochemical analysis of lung tissues.
53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2004) Gene set enrichment analysis. Proceedings of the National Academy of Sciences 101: 15440–15445.

52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PPARγ mediates cellular oxidative stress response. Nature genetics 33: 486–490.

47. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-associated molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793–2799.

45. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

44. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

38. Giangreco A, Groot KR, Janes SM (2007) Lung Cancer and Lung Stem Cells: Life in the Balance. Frontiers in Bioscience 12: 1981–1991.

30. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, et al. (2009) Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and cancer progression. Nat Rev Cancer 2: 161–174.

55. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of oncogenic K-ras. Genes Dev 15: 3243–3248.

54. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated high-grade human carcinomas by laser microdissection and microarray analysis. BMC Cancer 8: e2220.

53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2004) Gene set enrichment analysis. Proceedings of the National Academy of Sciences 101: 15440–15445.

52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PPARγ mediates cellular oxidative stress response. Nature genetics 33: 486–490.

47. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-associated molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793–2799.

45. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

44. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

38. Giangreco A, Groot KR, Janes SM (2007) Lung Cancer and Lung Stem Cells: Life in the Balance. Frontiers in Bioscience 12: 1981–1991.

30. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, et al. (2009) Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and cancer progression. Nat Rev Cancer 2: 161–174.

55. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of oncogenic K-ras. Genes Dev 15: 3243–3248.

54. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated high-grade human carcinomas by laser microdissection and microarray analysis. BMC Cancer 8: e2220.

53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2004) Gene set enrichment analysis. Proceedings of the National Academy of Sciences 101: 15440–15445.

52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PPARγ mediates cellular oxidative stress response. Nature genetics 33: 486–490.

47. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-associated molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793–2799.

45. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

44. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

38. Giangreco A, Groot KR, Janes SM (2007) Lung Cancer and Lung Stem Cells: Life in the Balance. Frontiers in Bioscience 12: 1981–1991.

30. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, et al. (2009) Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and cancer progression. Nat Rev Cancer 2: 161–174.

55. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of oncogenic K-ras. Genes Dev 15: 3243–3248.

54. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated high-grade human carcinomas by laser microdissection and microarray analysis. BMC Cancer 8: e2220.

53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2004) Gene set enrichment analysis. Proceedings of the National Academy of Sciences 101: 15440–15445.

52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PPARγ mediates cellular oxidative stress response. Nature genetics 33: 486–490.

47. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-associated molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793–2799.

45. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

44. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

38. Giangreco A, Groot KR, Janes SM (2007) Lung Cancer and Lung Stem Cells: Life in the Balance. Frontiers in Bioscience 12: 1981–1991.

30. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, et al. (2009) Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and cancer progression. Nat Rev Cancer 2: 161–174.

55. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of oncogenic K-ras. Genes Dev 15: 3243–3248.

54. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated high-grade human carcinomas by laser microdissection and microarray analysis. BMC Cancer 8: e2220.

53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2004) Gene set enrichment analysis. Proceedings of the National Academy of Sciences 101: 15440–15445.

52. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PPARγ mediates cellular oxidative stress response. Nature genetics 33: 486–490.

47. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-associated molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793–2799.

45. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

44. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of genomic cancer data with GenePattern. Genome Biology 5: R80.

38. Giangreco A, Groot KR, Janes SM (2007) Lung Cancer and Lung Stem Cells: Life in the Balance. Frontiers in Bioscience 12: 1981–1991.

30. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, et al. (2009) Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and cancer progression. Nat Rev Cancer 2: 161–174.

55. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of oncogenic K-ras. Genes Dev 15: 3243–3248.

54. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated high-grade human carcinomas by laser microdissection and microarray analysis. BMC Cancer 8: e2220.

53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2004) Gene set enrichment analysis. Proceedings of the National Academy of Sciences 101: 15440–15445.
84. Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, et al. (2009) Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 63: 32–38.

85. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I (2008) Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55: 2016–2027.